NCT06901648View on ClinicalTrials.gov

A Study of HS-20094 in Patients With T2DM

PHASE2CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

March 7, 2025

Study Completion Date

April 9, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

HS-20094

Administrated by subcutaneous injection once a week

DRUG

Dulaglutide

Administrated by subcutaneous injection once a week

DRUG

Palcebo

Administrated by subcutaneous injection once a week

Trial Locations (1)

Unknown

Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital), Tianjin

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY